Regeneron Pharmaceuticals, Inc. (REGN) Revenue by Segment
Regeneron Pharmaceuticals revenue by segment at a glance
In Q2 fiscal 2026 (the quarter ended June 30, 2026), Regeneron Pharmaceuticals's largest product or service was Collaboration Revenue, with $2.46 billion or 57% of revenue, up 31.9% from a year earlier. Next: Product (38%) and Other (5%).
The fastest-growing product or service from a year earlier was Collaboration Revenue (+31.9%).
From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q3 fiscal 2017.
Regeneron Pharmaceuticals, Inc.
REGN
Healthcare
Revenue breakdown
Fiscal quarters, from company filings
Regeneron Pharmaceuticals revenue by product or service, last 4 quarters
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Collaboration Revenue | $2.5B | $1.9B | $2.0B | $1.9B | 57% |
| Product | $1.6B | $1.5B | $1.6B | $1.6B | 38% |
| Other | $193.3M | $171.2M | $198.2M | $183.9M | 5% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Questions and answers
Which product or service makes the most money for Regeneron Pharmaceuticals?
Collaboration Revenue: $2.46 billion, or 57% of revenue, in Q2 fiscal 2026.
What are Regeneron Pharmaceuticals's main products and services?
By revenue in Q2 fiscal 2026: Collaboration Revenue (57%), Product (38%) and Other (5%).
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
